Tarceva

(erlotinib)

ApprovedSmall molecule

Erlotinib is used to treat certain types of lung cancer and pancreatic cancer by blocking proteins that help cancer cells grow and survive.[2] Tarceva is currently approved and in use across 41 indications[4].[1]

Tarceva is one of 536 small molecule programs targeting Lung Adenocarcinoma. It is currently in Approved.

Indications

621

Total Trials

Active Trials

535

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Lung AdenocarcinomaCompleted

Non-Small Cell Lung CancerCompleted

Advanced Solid TumorsCompleted

Non-Small Cell Squamous Lung CarcinomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Bronchoalveolar AdenocarcinomaApproved

Central Nervous System NeoplasmApproved

Malignant Colon NeoplasmApproved

Chronic Hepatitis C Virus InfectionApproved

Mouth NeoplasmApproved

Lung AdenocarcinomaApproved

Completed

Non-Small Cell Lung CancerApproved

Completed

Advanced Solid TumorsPhase 2

Completed

Non-Small Cell Squamous Lung CarcinomaPreclinical

Active, not recruiting

Pancreatic NeoplasmApproved

Active, not recruiting

Bronchoalveolar AdenocarcinomaApproved

Approved

Central Nervous System NeoplasmApproved

Approved

Malignant Colon NeoplasmApproved

Approved

Chronic Hepatitis C Virus InfectionApproved

Approved

Mouth NeoplasmApproved

Approved

Showing 10 of 41 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Tarceva

OOSI Pharmaceuticals

Approved

175 2

Tuoyi

CCoherus Oncology, Inc.

Phase 3

9 3

Monalizumab

AstraZeneca

Phase 3

5 4

SKB264

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3

5 5

Remeron

OOrganon and Co

Preclinical

1 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Metastatic NSCLC

NCT02411448

Q1 2027

Phase 2Recruiting

Trial

NCT03297606

Q3 2027

Phase 1/2Recruiting

Nab-Paclitaxel

NCT06483555

Q4 2027

Phase 2Recruiting

Trial

NCT02925234

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer64 trials

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Completed·UUniversity of Utah·Phase 1·NCT01998126·14 enrolled

A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT00940875·54 enrolled

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Completed·—·Phase 3·NCT00153803·245 enrolled

Show 61 more trials

A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 4·NCT01196078·114 enrolled

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Terminated· Roche logo

Roche·Phase 2·NCT00760929·171 enrolled

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT00883779·451 enrolled

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT02031744·530 enrolled

A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 4·NCT01066884·5 enrolled

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04179890·462 enrolled

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Completed· Roche logo

Roche·Phase 4·NCT01287754·24 enrolled

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01454102·472 enrolled

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis

Completed· Roche logo

Roche·Phase 2·NCT00800202·91 enrolled

Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer

Unknown status·—·Phase 2·NCT00466089·90 enrolled

A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer

Completed·UUniversity of Utah·Phase 2·NCT00585533·40 enrolled

A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Completed· Roche logo

Roche·Phase 2·NCT01998919·154 enrolled

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT00556322·424 enrolled

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)

Completed· Roche logo

Roche··NCT01836133·70 enrolled

A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy

Completed· Roche logo

Roche·Phase 2·NCT01174563·60 enrolled

A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00531934·147 enrolled

A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

Completed· Roche logo

Roche·Phase 3·NCT01183858·315 enrolled

A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 2·NCT01996332·1,805 enrolled

A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)

Completed· Roche logo

Roche·Phase 2·NCT01204697·74 enrolled

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

Terminated· Roche logo

Roche·Phase 2·NCT00773383·35 enrolled

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting·OOBI Pharma, Inc·Phase 2·NCT05442060·60 enrolled

A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT00556712·889 enrolled

A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01897480·168 enrolled

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

Unknown status·GGuangdong Association of Clinical Trials·Phase 2/3·NCT01407822·72 enrolled

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

Completed·OOntario Clinical Oncology Group (OCOG)·Phase 2·NCT00391248·40 enrolled

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01822496·59 enrolled

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT02039674·267 enrolled

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Completed· Roche logo

Roche·Phase 1/2·NCT01801111·138 enrolled

A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy

Completed· Roche logo

Roche·Phase 2·NCT02013206·52 enrolled

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Terminated·—·Phase 2·NCT00830245·20 enrolled

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Completed·TTongji University·Phase 3·NCT00874419·165 enrolled

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

Completed· Roche logo

Roche·Phase 2·NCT01378962·50 enrolled

Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00749567·13 enrolled

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00411632·37 enrolled

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00609804·53 enrolled

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Completed· Roche logo

Roche·Phase 2·NCT01260181·30 enrolled

Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer

Unknown status·GGuangdong Provincial People's Hospital·Phase 2·NCT00663689·45 enrolled

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Completed·—·Phase 2·NCT01532089·88 enrolled

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Terminated· Novartis logo

Novartis·Phase 1·NCT02468661·23 enrolled

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT02277457

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00547105·24 enrolled

Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer

Completed·SSamsung Medical Center·Phase 2·NCT01130753·43 enrolled

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT01667562·375 enrolled

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Terminated·—·Phase 1·NCT02206763·11 enrolled

A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT00701558·20 enrolled

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT01351415·485 enrolled

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00553800·32 enrolled

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01294306·80 enrolled

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00088959·45 enrolled

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02296125·674 enrolled

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Completed·UUniversity of California, Davis·Phase 1/2·NCT00390429·81 enrolled

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Completed·NNorthwestern University·Phase 1/2·NCT01259089·38 enrolled

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00280150·46 enrolled

Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases

Withdrawn·UUniversity of California, San Francisco·Phase 1·NCT00738335

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Terminated· Takeda logo

Takeda·Phase 2·NCT00283634

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00416650·16 enrolled

Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT00499655·107 enrolled

RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01193881·16 enrolled

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00397384·43 enrolled

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00445848·89 enrolled

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00444015·34 enrolled

Lung Cancer11 trials

Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT01556191·379 enrolled

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Withdrawn· GSK logo

GSK·Phase 2·NCT02034097

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Terminated·—·Phase 2·NCT02770014·43 enrolled

Show 8 more trials

Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer

Completed·BBritish Columbia Cancer Agency·Phase 2·NCT00473083·150 enrolled

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00147537·282 enrolled

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT02044601

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT00983307·17 enrolled

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01967095·53 enrolled

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00965731·27 enrolled

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01189435·2 enrolled

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Terminated·SSWOG Cancer Research Network·Phase 2/3·NCT02926638·9 enrolled

Pancreatic Cancer10 trials

ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer

Completed· Roche logo

Roche·Phase 1·NCT00925769·32 enrolled

A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Terminated· Roche logo

Roche·Phase 4·NCT00642733·6 enrolled

Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00634725·820 enrolled

Show 7 more trials

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

Completed·—·Phase 1·NCT02154737·24 enrolled

A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

Terminated·—·Phase 2·NCT00336700·25 enrolled

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT01729481·150 enrolled

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Completed· Roche logo

Roche·Phase 3·NCT02694536·80 enrolled

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01013649·546 enrolled

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00063947·28 enrolled

Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00470535·18 enrolled

Breast Cancer8 trials

A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

Completed· Roche logo

Roche·Phase 2·NCT00109265

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

Completed·—·Phase 1·NCT01650506·8 enrolled

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00574366·14 enrolled

Show 5 more trials

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Completed·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT00033514·27 enrolled

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054132·38 enrolled

Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00059852·61 enrolled

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

Unknown status·UUniversity of Kansas Medical Center·Phase 2·NCT00491816·32 enrolled

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00030537

Lung Adenocarcinoma7 trials

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Completed·SSi-Yu Wang·Phase 2·NCT01565538·123 enrolled

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Completed· Roche logo

Roche·Phase 4·NCT01609543·62 enrolled

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Unknown status·NNational Cheng-Kung University Hospital·N/A·NCT00903292·52 enrolled

Show 4 more trials

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03076164·24 enrolled

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02155465·22 enrolled

Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Completed·GGuangzhou Medical University·Phase 2·NCT01578668·69 enrolled

A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma

Unknown status·MMedicalLogic·Phase 2·NCT02146118·42 enrolled

71 more indications

Advanced Solid Tumors4 trials

Study of ABT-700 in Subjects With Advanced Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT01472016·74 enrolled

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Terminated· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT04165031·5 enrolled

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Completed· Roche logo

Roche·Phase 2·NCT02091141·673 enrolled

Show 1 more trial

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT02099058·237 enrolled

Small Cell Lung Cancer4 trials

Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)

Completed·HHellenic Oncology Research Group·Phase 3·NCT00440414·320 enrolled

Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Unknown status·SSun Yat-sen University·Phase 2·NCT02066038·60 enrolled

Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment

Completed·MMeir Medical Center·Phase 2·NCT00840125·4 enrolled

Show 1 more trial

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01900652·111 enrolled

Bevacizumab4 trials

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

Unknown status·—·Phase 2·NCT05904457·32 enrolled

Bevacizumab in Multiple Phase I Combinations

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00543504·343 enrolled

Molecular Imaging With Erlotinib and Bevacizumab

Completed·UUniversity of Cologne·Phase 2·NCT01047059·40 enrolled

Show 1 more trial

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00436332·84 enrolled

Liver Cancer3 trials

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Completed·MMedical University of South Carolina·Phase 2·NCT00881751·95 enrolled

A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00605722·51 enrolled

Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00047333·80 enrolled

Metastatic Colorectal Cancer3 trials

Pemetrexed and Erlotinib for Metastatic Colorectal Cancer

Completed·YYonsei University·Phase 2·NCT02723578·50 enrolled

Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00642746·16 enrolled

Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00049101

Efficacy and Safety2 trials

Efficacy and Safety of Precision Therapy in Refractory Tumor

Unknown status·BBaodong Qin·Phase 2·NCT03239015·300 enrolled

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

Unknown status·LLi Zhang·Phase 2·NCT02006043·54 enrolled

Activating EGFR Mutation2 trials

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Completed·BBaohui Han·Phase 2·NCT01217619·25 enrolled

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

Completed·GGuangdong Association of Clinical Trials·Phase 3·NCT02759614·311 enrolled

Patients With Advanced Solid Tumors2 trials

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT00811993·104 enrolled

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT00975182·58 enrolled

Hepatocellular Carcinoma2 trials

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Completed· Bayer logo

Bayer·Phase 3·NCT00901901·732 enrolled

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01180959·45 enrolled

Colorectal Cancer2 trials

Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

Completed· Roche logo

Roche·Phase 1·NCT00047762

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Completed·NNorthwestern University·Phase 2·NCT00940316·28 enrolled

Ovarian Cancer2 trials

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Completed·UUniversity of Arizona·Phase 2·NCT00130520·40 enrolled

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Terminated·NNYU Langone Health·Phase 2·NCT01003938·6 enrolled

Nab-paclitaxel2 trials

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Completed· GSK logo

GSK·Phase 1·NCT01192165·169 enrolled

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT06483555·104 enrolled

Recurrent Head and Neck Cancer2 trials

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00055770·45 enrolled

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Completed·JJohnny Kao·Phase 1/2·NCT00970502·15 enrolled

Locally-advanced Rectal Cancer2 trials

Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Completed·MMassachusetts General Hospital·Phase 1/2·NCT00307736·32 enrolled

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00543842·19 enrolled

Trial2 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03297606·720 enrolled

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Head and Neck Cancer2 trials

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Completed·WWake Forest University Health Sciences·Phase 1·NCT00601913·24 enrolled

Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Completed·UUniversity of Washington·Phase 2·NCT00410826·204 enrolled

NSCLC2 trials

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 3·NCT02140333·220 enrolled

Erlotinib and Sunitinib in NSCLC

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT00581789·11 enrolled

Metastatic NSCLC2 trials

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Completed·TThe University of Hong Kong·Phase 2·NCT02625168·25 enrolled

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT02411448·545 enrolled

Advanced NSCLC2 trials

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Completed·CChinese Society of Lung Cancer·Phase 3·NCT01024413·256 enrolled

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Terminated·IIo Therapeutics·Phase 1·NCT02991651·12 enrolled

Squamous Cell Carcinoma2 trials

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00079053·19 enrolled

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01064479·123 enrolled

Adenocarcinoma1 trial

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Completed·SShanghai University of Traditional Chinese Medicine·Phase 3·NCT02889692·23 enrolled

Kidney Cancer1 trial

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01688973·55 enrolled

Age1 trial

A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.

Completed· Roche logo

Roche·Phase 3·NCT00718315·201 enrolled

Advanced Cancers1 trial

Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract

Completed·—·Phase 1·NCT01116622·24 enrolled

Sclerosing Cholangitis1 trial

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Completed·MMayo Clinic·Phase 1·NCT00955149·6 enrolled

Growth1 trial

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Completed· Roche logo

Roche·Phase 2·NCT01372384·6 enrolled

EGFR Mutation1 trial

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT01683175·94 enrolled

Malignant Glioma1 trial

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Completed·—·Phase 1·NCT01257594·22 enrolled

Prevention1 trial

A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash

Completed· Roche logo

Roche·Phase 2·NCT00642473·34 enrolled

Nasopharyngeal Cancer1 trial

A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00603915·20 enrolled

Ependymoma1 trial

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Terminated·OOSI Pharmaceuticals·Phase 2·NCT01032070·25 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT00620269·212 enrolled

Adjuvant Treatment1 trial

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Unknown status·CChinese Lung Cancer Surgical Group·Phase 2·NCT01410214·80 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT00369512·15 enrolled

Germ Cell Tumor1 trial

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

Terminated·TTheodore Laetsch·Phase 2·NCT01962896·4 enrolled

Metastatic1 trial

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Terminated·TThe Methodist Hospital Research Institute·Phase 1/2·NCT00522249·10 enrolled

Refractory Solid Tumors1 trial

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Completed·SSCRI Development Innovations, LLC·Phase 1·NCT00759928·48 enrolled

Gastroesophageal Junction1 trial

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

Terminated·WWashington University School of Medicine·Phase 2·NCT00442507·6 enrolled

Immunotherapy1 trial

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Unknown status·FFondazione per la Medicina Personalizzata·Phase 2·NCT04591431·400 enrolled

Metastatic Prostate Cancer1 trial

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

Completed·EEndeavor Health·Phase 2·NCT00148772·29 enrolled

Squamous Cell Cancer1 trial

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01059305·10 enrolled

Resistance1 trial

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Completed·—·Phase 2·NCT00997334·60 enrolled

Radiation Therapy1 trial

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00766636·5 enrolled

Stage IB-IIIA NSCLC1 trial

Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00577707·9 enrolled

Pediatric Solid Tumors1 trial

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Withdrawn·WWashington University School of Medicine·Phase 2·NCT02689336

Head Neck Cancer1 trial

Treatment of Head & Neck Cancer With Chemotherapy and Radiation

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00392704·60 enrolled

Oral Cancer1 trial

Erlotinib Prevention of Oral Cancer (EPOC)

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00402779·303 enrolled

Familial adenomatous polyposis1 trial

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02961374·46 enrolled

Tics1 trial

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT00600496·140 enrolled

Effectiveness1 trial

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Unknown status·FFudan University·Phase 2·NCT02037997·80 enrolled

Treatment1 trial

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Completed·FFinnish Lung Cancer Group·Phase 2·NCT02064491·18 enrolled

Head and Neck Squamous Cell Cancer1 trial

A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer

Terminated· Roche logo

Roche·Phase 3·NCT00412217·94 enrolled

Clinical Trial1 trial

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting·UUlrik Lassen·Phase 2·NCT04341181·300 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01927744·55 enrolled

Glioma1 trial

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

Unknown status·AAmsterdam UMC, location VUmc·N/A·NCT02239952·15 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Terminated·—·Phase 2·NCT01182350·53 enrolled

Brain Metastases1 trial

Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases

Unknown status·WWu Jieping Medical Foundation·Phase 2·NCT01763385·210 enrolled

NSCLC Stage III1 trial

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Completed·HHellenic Oncology Research Group·Phase 2·NCT00615758·50 enrolled

Recurrent or Refractory Solid Tumors1 trial

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00077454·95 enrolled

Urothelial Cancer1 trial

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00749892·34 enrolled

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00320073·41 enrolled

Glioblastoma Multiforme1 trial

A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)

Completed· Roche logo

Roche·Phase 2·NCT00337883·110 enrolled

Gastroesophageal Junction Cancer1 trial

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00032123

Unresectable1 trial

Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00356889·56 enrolled

Cholangiocarcinoma1 trial

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01093222·40 enrolled

Transplantation1 trial

Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT07418177·9 enrolled

Solid Tumor Malignancies1 trial

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Completed·NNew Mexico Cancer Research Alliance·Phase 1·NCT00996515·30 enrolled

Radiotherapy1 trial

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Unknown status·GGuangdong Provincial People's Hospital·Phase 2/3·NCT03074864·90 enrolled

Unspecified2 trials

The Continuation of Erlotinib

Unknown status·SSamsung Medical Center·Phase 2·NCT01130779·23 enrolled

Erlotinib in Combination With Cetuximab

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00895362·65 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 18, 2004

TARCEVA

NDA NDA021743

Sources

References

[1]
ClinicalTrials.gov — 621 trial records for erlotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Tarceva drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — erlotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for erlotinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021743). U.S. Food & Drug Administration.
[6]
SEC EDGAR — OSI Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Epidermal Growth Factor Receptor Erbb1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: OOSI Pharmaceuticals

Tarceva

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer64 trials

Lung Cancer11 trials

Pancreatic Cancer10 trials

Breast Cancer8 trials

Lung Adenocarcinoma7 trials

Advanced Solid Tumors4 trials

Small Cell Lung Cancer4 trials

Bevacizumab4 trials

Liver Cancer3 trials

Metastatic Colorectal Cancer3 trials

Efficacy and Safety2 trials

Activating EGFR Mutation2 trials

Patients With Advanced Solid Tumors2 trials

Hepatocellular Carcinoma2 trials

Colorectal Cancer2 trials

Ovarian Cancer2 trials

Nab-paclitaxel2 trials

Recurrent Head and Neck Cancer2 trials

Locally-advanced Rectal Cancer2 trials

Trial2 trials

Head and Neck Cancer2 trials

NSCLC2 trials

Metastatic NSCLC2 trials

Advanced NSCLC2 trials

Squamous Cell Carcinoma2 trials

Adenocarcinoma1 trial

Kidney Cancer1 trial

Age1 trial

Advanced Cancers1 trial

Sclerosing Cholangitis1 trial

Growth1 trial

EGFR Mutation1 trial

Malignant Glioma1 trial

Prevention1 trial

Nasopharyngeal Cancer1 trial

Ependymoma1 trial

Induction Chemotherapy1 trial

Adjuvant Treatment1 trial

Cutaneous Squamous Cell Carcinoma1 trial

Germ Cell Tumor1 trial

Metastatic1 trial

Refractory Solid Tumors1 trial

Gastroesophageal Junction1 trial

Immunotherapy1 trial

Metastatic Prostate Cancer1 trial

Squamous Cell Cancer1 trial

Resistance1 trial

Radiation Therapy1 trial

Stage IB-IIIA NSCLC1 trial

Pediatric Solid Tumors1 trial

Head Neck Cancer1 trial

Oral Cancer1 trial

Familial adenomatous polyposis1 trial

Tics1 trial

Effectiveness1 trial

Treatment1 trial

Head and Neck Squamous Cell Cancer1 trial

Clinical Trial1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Glioma1 trial

Diffuse Intrinsic Pontine Glioma1 trial

Brain Metastases1 trial

NSCLC Stage III1 trial

Recurrent or Refractory Solid Tumors1 trial

Urothelial Cancer1 trial

Fallopian Tube Cancer1 trial

Cervical Cancer1 trial

Metastatic Solid Tumors1 trial

Glioblastoma Multiforme1 trial

Gastroesophageal Junction Cancer1 trial

Unresectable1 trial